Premium
The momentous role of N6‐methyladenosine in lung cancer
Author(s) -
Xu Ruiyao,
Pang Gaozong,
Zhao Qing,
Yang Lin,
Chen Shu,
Jiang Long,
Shen Yuxian,
Shao Wei
Publication year - 2021
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.30136
Subject(s) - lung cancer , methyltransferase , carcinogenesis , cancer , treatment of lung cancer , biology , ectopic expression , cancer research , bioinformatics , causes of cancer , medicine , computational biology , gene , genetics , oncology , methylation
Lung cancer is the leading cause of cancer death worldwide. Although diagnostic methods and targeted drugs have been rapidly developed in recent years, the underlying molecular mechanisms in the pathogenesis of lung cancer remain enigmatic. The N6‐methyladenosine (m 6 A) modification is the most common modification of messenger RNA in eukaryotes and plays critical roles in many diseases, especially cancers. Ectopic m 6 A modification is associated with human carcinogenesis, including lung cancer. The m 6 A modification is mediated by methyltransferases (writers) and demethylases (erasers) and indirectly affects biological processes through the recruitment of specific reader proteins (readers). Many studies have shown that m 6 A writers, erasers, and readers serve as specific and sensitive biomarkers for lung cancer diagnosis, prognosis, and therapy. This review summarizes recent studies on the biological functions of the m 6 A modification in lung cancer and discusses the potential application of m 6 A regulators in lung cancer diagnosis and therapeutics.